226H (ATCC® HB-12592)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Applications
This antibody is specific for the rat subunit integrin alphaD.
It may be used to inhibit inflammation at the site of a central nervous system injury.
Derivation
Animals were immunized with purified rat alphaD subunit.
Spleen cells were fused with NS-1 mouse myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 (alphaDbeta2) integrin
Cellular Products
immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 (alphaDbeta2) integrin
Comments
Animals were immunized with purified rat alphaD subunit.
Spleen cells were fused with NS-1 mouse myeloma cells.
This antibody is specific for the rat subunit integrin alphaD.
It may be used to inhibit inflammation at the site of a central nervous system injury.
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 85%; heat-inactivated fetal bovine serum, 15%
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Cryopreservation
Culture medium supplemented with an additional 50% heat-inactivated fetal bovine serum and 10% DMSO
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain
Name of Depositor ICOS Corporation
References

Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001

Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. PubMed: 11031083

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001

Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. PubMed: 11031083